CTMX
insider transactionsCytomX Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-192.7K
0 buy · 192.7K sell
Net value · 365d
-$1.2M
$0 in · $1.2M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
5
0 buy · 192.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Financial Officer
$5.0K
1.6K sh · $3.05
Own -1%
-
Sell·S
Sean A. Mccarthy KEY
CEO · 10b5-1
$764.1K
119.0K sh · $6.42
Own -10%
-
Sell·S
Chief Financial Officer
$124.1K
19.3K sh · $6.42
Own -6%
-
Sell·S
Chief Medical Officer
$136.7K
21.3K sh · $6.42
Own -10%
-
Sell·S
SVP, Chief Scientific Officer
$202.3K
31.5K sh · $6.42
Own -9%
-
Grant·A
Chief Business Officer
$0
50.0K sh
Own New
-
Grant·A
Chief Business Officer
$0
20.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
325.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
90.0K sh
Own +40%
-
Grant·A
Sean A. Mccarthy KEY
CEO
$0
980.0K sh
Own New
-
Grant·A
Sean A. Mccarthy KEY
CEO
$0
210.0K sh
Own +21%
-
Grant·A
Chief Medical Officer
$0
300.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
75.0K sh
Own +55%
-
Grant·A
SVP, Chief Scientific Officer
$0
250.0K sh
Own New
-
Grant·A
SVP, Chief Scientific Officer
$0
60.0K sh
Own +22%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogden KEY | Sell S | 1.6K | $5.0K |
| Mar 17, 2026 | Sean A. Mccarthy KEY 10b5-1 | Sell S | 119.0K | $764.1K |
| Mar 17, 2026 | Christopher Ogden KEY | Sell S | 19.3K | $124.1K |
| Mar 17, 2026 | Yu-Waye Chu | Sell S | 21.3K | $136.7K |
| Mar 17, 2026 | Marcia Belvin | Sell S | 31.5K | $202.3K |
| Feb 2, 2026 | Rachael Lester | Grant A | 50.0K | $0 |
| Feb 2, 2026 | Rachael Lester | Grant A | 20.0K | $0 |
| Feb 2, 2026 | Christopher Ogden KEY | Grant A | 325.0K | $0 |
| Feb 2, 2026 | Christopher Ogden KEY | Grant A | 90.0K | $0 |
| Feb 2, 2026 | Sean A. Mccarthy KEY | Grant A | 980.0K | $0 |
| Feb 2, 2026 | Sean A. Mccarthy KEY | Grant A | 210.0K | $0 |
| Feb 2, 2026 | Yu-Waye Chu | Grant A | 300.0K | $0 |
| Feb 2, 2026 | Yu-Waye Chu | Grant A | 75.0K | $0 |
| Feb 2, 2026 | Marcia Belvin | Grant A | 250.0K | $0 |
| Feb 2, 2026 | Marcia Belvin | Grant A | 60.0K | $0 |
About CTMX insider trading
This page tracks insider transactions for CytomX Therapeutics, Inc. (CTMX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.